Shanghai, 3rd December 2018. Elpiscience announced today that it has completed a 35 million USD series A+ round of financing led by Hillhouse Capital, with participation from CDH Investments and existing investor Lilly Asia Ventures (LAV). Together with 20 million USD raised in the series A round led by LAV, this financing brings the total funds to 55 million USD. Proceeds will be primarily used to advance its pipeline, including ES101 for which a Phase I clinical trial is planned to start in early 2019.
Elpiscience, has developed a pipeline of 12 R&D programs covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies.
Dr. Darren Ji, co-founder and CEO of Elpiscience, said, “We extended our deepest thanks to Hillhouse, LAV and CDH for their support and recognition. They are certainly recognized as the best investors, have significant resources in healthcare industry with extensive experience, expertise, influence and strategic insight in China and global market. There is no doubt that endorsements from the top-tier investors definitely boost our value and step up our pace to be the most leading cancer immunotherapy company.”
Elpiscience is a top-tier investor backed biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience’s innovations cover a wide range of immunology targets with a focus on innate immunity and tumor microenvironment.
Hillhouse Capital is a global Asia-focused private equity firm founded by Lei Zhang in 2005. Hillhouse Capital is a global firm of investment professionals and operating executives who are focused on building and investing in high quality business franchises that achieve sustainable growth. Independent proprietary research and industry expertise, in conjunction with world-class operating and management capabilities, are key to Hillhouse Capital’s investment approach. Hillhouse Capital partners with exceptional entrepreneurs and management teams to create value, often with a focus on enacting technological transformation and innovation. Hillhouse Capital invests in the consumer, technology, media and telecommunications, healthcare, advanced manufacturing, financial and business services sectors in companies across all equity stages. For more information, please visit www.hillhousecap.com.